

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

1-6. (canceled)

7. (currently amended) A peptide compound comprising a sequence of at least 8 consecutive amino acids ~~of a natural hsp70 sequence, the sequence having at least one mutation or modification with respect to, and having at least 80% homology with, the amino acids sequence comprised between amino acids 286 and 294 of natural hsp70,~~ said peptide being able to induce a specific T-cell immune response, the amino acid sequence being selected from the group consisting of SLFEGIDIY (SEQ ID No 1) and SLFEGIDIYT (SEQ ID No 2).

8-9. (canceled)

10. (currently amended) The peptide compound as claimed in claim 7 ~~[[9]]~~, wherein the amino acid sequence is SEQ ID No. 1.

11. (currently amended) The peptide compound as claimed in claim 7, further comprising at least one element selected from the group consisting of:

- a protective chemical group able to protect peptides against proteases and reacting with [the] NH<sub>2</sub> or COOH, or with both NH<sub>2</sub> and COOH, provided that this modification does not significantly lower the immunogenicity of the peptide,

- a chemical groups ~~group~~ improving the effectiveness of a vaccine in vivo,

81  
- lipids or fatty acids, covalently linked to the peptide fragments so as to form lipopeptides,

- a carrier protein possessing restriction sites and enabling intact peptide fragments to be conveyed to their sites of action in the body.

12. (canceled)

13. (previously presented) A vector for expressing the peptide compound as claimed in claim 7, comprising a DNA fragment encoding for said peptide compound, wherein the DNA fragment is fused to a promoter that is strong and effective in eukaryotic or in

prokaryotic cells or in both eukaryotic and prokaryotic cells.

14. (previously presented) The vector as claimed in claim 13, further comprising at least one selection marker and, optionally, at least one coding sequence for cytokines or lymphokines or for both cytokines and lymphokines.

15. (previously presented) The vector as claimed in claim 13, wherein the vector is chosen from a viral vector, a plasmid, and a pseudovector.

Σ' 21  
16-18. (canceled)

~~19.~~ (previously presented) A pharmaceutical composition comprising a peptide compound according to claim 7 and a pharmaceutically acceptable vehicle.

~~20.~~ (previously presented) The pharmaceutical composition as claimed in claim 19, further comprising at least one immunological adjuvant.

~~21.~~ (previously presented) A pharmaceutical composition comprising a vector as claimed in claim 13 and a pharmaceutically acceptable vehicle.

22-29. (canceled)

~~30.~~ (previously presented) The pharmaceutical composition comprising a pharmaceutical vehicle which is compatible with IV, subcutaneous, oral or nasal administration.

EL 31. (previously presented) The pharmaceutical composition as claimed in claim 19 further comprising a pharmaceutical vehicle chosen from positively charged liposomes, negatively charged liposomes, nanoparticles, and lipid emulsions.

32-33. (canceled)

~~34.~~ (currently amended) A method for ~~immunizing~~ ~~at a distance from~~ systemic immunization of a tumor(s), comprising administering to a patient a medicinal product comprising a peptide compound comprising a sequence of at least 8 consecutive amino acids, the amino acid sequence

being selected from the group consisting of SLFEGIDIIY (SEQ ID No 1) and SLFEGIDIYT (SEQ ID No 2) of a natural hsp70 sequence the sequence having at least one mutation or modification with respect to the natural hsp70 sequence, and wherein the peptide compound brings about a specific T-cell immune response.

El  
25. (currently amended) A method for immunizing by direct injection in a tumor(s) ~~or at an immediate vicinity near a tumor(s)~~, comprising administering to a patient a medicinal product comprising a sequence of at least 8 consecutive amino acids, the amino acid sequence being selected from the group consisting of SLFEGIDIIY (SEQ ID No 1) and SLFEGIDIYT (SEQ ID No 2) of a natural hsp70 sequence the sequence having at least one mutation or modification with respect to the natural hsp70 sequence, and wherein the peptide compound brings about a specific T-cell immune response.

36-63. (canceled)

64. (previously presented) A pharmaceutical composition comprising a peptide compound according to claim 10 [[8]] and a pharmaceutically acceptable vehicle.

E1  
A

65. (canceled)

---